Aosaikang Biotherapeutics

Aosaikang Biotherapeutics, often referred to as Ask Pharm, is a leading Chinese pharmaceutical company specializing in the development, manufacturing, and commercialization of innovative drugs and high-end generics. The company maintains a strong focus on oncology, gastroenterology, and chronic disease management, with a robust pipeline of biologics and small molecules. Aosaikang operates integrated R&D centers in Beijing and Nanjing, as well as international collaborations through its subsidiary AskGene Pharma in the United States. Its portfolio includes several marketed products in China, particularly in the anti-tumor and digestive system segments, while its clinical pipeline features advanced candidates targeting Claudin 18.2 and EGFR mutations.